Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.
Treatment with the chimeric anti-CD20 monoclonal antibody rituximab induces rapid and long-lasting depletion of circulating B cells. We report the occurrence of enteroviral meningoencephalitis following rituximab therapy in 1 child with immune thrombocytopenia and in 1 adult patient with relapsed B cell lymphoma.
Quartier
Pierre
P
Unité d'Immunologie-Hématologie et Rhumatologie Pédiatrique, Hôpital Necker-Enfants Malades, 75 743 Paris cedex 15, France. quartier@necker.fr
Tournilhac
Olivier
O
Archimbaud
Christine
C
Lazaro
Leila
L
Chaleteix
Carine
C
Millet
Pascale
P
Peigue-Lafeuille
Hélène
H
Blanche
Stéphane
S
Fischer
Alain
A
Casanova
Jean-Laurent
JL
Travade
Philippe
P
Tardieu
Marc
M
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D006801:Humans; D008590:Meningoencephalitis / Q000139:chemically induced*; D008875:Middle Aged; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab